JP2008539191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008539191A5 JP2008539191A5 JP2008508192A JP2008508192A JP2008539191A5 JP 2008539191 A5 JP2008539191 A5 JP 2008539191A5 JP 2008508192 A JP2008508192 A JP 2008508192A JP 2008508192 A JP2008508192 A JP 2008508192A JP 2008539191 A5 JP2008539191 A5 JP 2008539191A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- tartrate
- magnesium
- acetyl
- fumarate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002253 acid Substances 0.000 claims 9
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical class CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 2
- -1 mucate Substances 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 229940095064 tartrate Drugs 0.000 claims 2
- NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 claims 1
- MOMFXATYAINJML-UHFFFAOYSA-N 2-Acetylthiazole Chemical group CC(=O)C1=NC=CS1 MOMFXATYAINJML-UHFFFAOYSA-N 0.000 claims 1
- XOAAWQZATWQOTB-UHFFFAOYSA-M 2-aminoethanesulfonate Chemical compound NCCS([O-])(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-M 0.000 claims 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 229960004203 carnitine Drugs 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229960005336 magnesium citrate Drugs 0.000 claims 1
- 235000002538 magnesium citrate Nutrition 0.000 claims 1
- 239000004337 magnesium citrate Substances 0.000 claims 1
- 229940095060 magnesium tartrate Drugs 0.000 claims 1
- MUZDLCBWNVUYIR-ZVGUSBNCSA-L magnesium;(2r,3r)-2,3-dihydroxybutanedioate Chemical compound [Mg+2].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O MUZDLCBWNVUYIR-ZVGUSBNCSA-L 0.000 claims 1
- QUIOHQITLKCGNW-TYYBGVCCSA-L magnesium;(e)-but-2-enedioate Chemical compound [Mg+2].[O-]C(=O)\C=C\C([O-])=O QUIOHQITLKCGNW-TYYBGVCCSA-L 0.000 claims 1
- YZURQOBSFRVSEB-UHFFFAOYSA-L magnesium;2-aminoethanesulfonate Chemical compound [Mg+2].NCCS([O-])(=O)=O.NCCS([O-])(=O)=O YZURQOBSFRVSEB-UHFFFAOYSA-L 0.000 claims 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940066528 trichloroacetate Drugs 0.000 claims 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims 1
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05009056 | 2005-04-26 | ||
| PCT/EP2006/061632 WO2006114372A1 (en) | 2005-04-26 | 2006-04-18 | Acetyl l-carnitine for preventing painful peripheral diabetic neuropathy |
| EP05009056.2 | 2006-04-26 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014207378A Division JP2015025004A (ja) | 2005-04-26 | 2014-10-08 | 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008539191A JP2008539191A (ja) | 2008-11-13 |
| JP2008539191A5 true JP2008539191A5 (enExample) | 2009-06-04 |
| JP5685362B2 JP5685362B2 (ja) | 2015-03-18 |
Family
ID=35044927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008508192A Expired - Fee Related JP5685362B2 (ja) | 2005-04-26 | 2006-04-18 | 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン |
| JP2014207378A Withdrawn JP2015025004A (ja) | 2005-04-26 | 2014-10-08 | 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014207378A Withdrawn JP2015025004A (ja) | 2005-04-26 | 2014-10-08 | 有痛性末梢糖尿病性神経障害の予防のためのアセチルl−カルニチン |
Country Status (1)
| Country | Link |
|---|---|
| JP (2) | JP5685362B2 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1302307B1 (it) * | 1998-09-01 | 2000-09-05 | Sigma Tau Healthscience Spa | Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil |
| ITRM20010293A1 (it) * | 2001-05-29 | 2002-11-29 | Sigma Tau Ind Farmaceuti | Uso della acetil-l-carnetina per la preparazione di un medicamento per la prevenzione del dolore. |
| CA2531056A1 (en) * | 2002-10-11 | 2004-04-22 | Creagri, Inc. | Therapeutic combination of carnitine and antioxidant polyphenols |
-
2006
- 2006-04-18 JP JP2008508192A patent/JP5685362B2/ja not_active Expired - Fee Related
-
2014
- 2014-10-08 JP JP2014207378A patent/JP2015025004A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112020001285A2 (pt) | s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização | |
| FI3164125T3 (fi) | Menetelmiä ja koostumuksia liikalihavuuden hoitamiseksi, painonnousun ehkäisemiseksi, painonpudotuksen edistämiseksi, laihtumisen edistämiseksi tai diabeteksen hoitamiseksi tai sen kehittymisen ehkäisemiseksi | |
| JP2006506361A5 (enExample) | ||
| CN104667283B (zh) | 一种治疗血脂异常和动脉粥样硬化的复方药物组合 | |
| US8053472B2 (en) | Use of the acetyl L-carnitine in association with the biotin for the treatment of patients with type 2 insulin-resistant diabetes mellitus | |
| CN1299283A (zh) | 包含l-肉毒碱或烷酰基l-肉毒碱和nadh和/或nadph的组合物 | |
| JP2004532866A5 (enExample) | ||
| CN104220059A (zh) | 通过给予屈昔多巴来改善姿势稳定性 | |
| JP2008539191A5 (enExample) | ||
| JP2008505134A5 (enExample) | ||
| JP2006505499A5 (enExample) | ||
| JP2006523685A5 (enExample) | ||
| JP2006511531A5 (enExample) | ||
| JP2004532865A5 (enExample) | ||
| JP2008534433A5 (enExample) | ||
| JP2014040442A (ja) | 2型糖尿病の処置に有用な組成物 | |
| JP2010519333A5 (enExample) | ||
| CA2478674A1 (en) | Combined use of l-carnitine, acetyl l-carnitine and propionyl l-carnitine for the treatment of oligoasthenoteratospermia | |
| ES2359910T3 (es) | Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso. | |
| ES2267796T3 (es) | Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva. | |
| JP2007523176A5 (enExample) | ||
| JP2008517872A5 (enExample) | ||
| CN101087602B (zh) | L-肉碱和葡萄糖治疗心血管疾病的应用 | |
| ES2320788T3 (es) | Uso de l-acetilcarnitina para el tratamiento del sindrome fibromialgico. | |
| JP2003501385A5 (enExample) |